Which selective serotonin reuptake inhibitors (SSRIs) are recommended for a postpartum patient who is breastfeeding, and what are the appropriate starting doses?

SSRI Use During Breastfeeding

Paroxetine and sertraline are the preferred SSRIs for breastfeeding mothers, with paroxetine showing the most favorable safety profile (infant-to-maternal plasma ratio uniformly <0.10) and sertraline also demonstrating minimal excretion into breast milk. 1

Recommended First-Line Agents

Paroxetine

• Uniformly lowest infant exposure among all SSRIs with infant-to-maternal plasma concentration ratio consistently <0.10 1
• Minimal excretion in breast milk, providing infant <10% of maternal daily dose (weight-normalized) 1
• Most consistently recommended across multiple systematic reviews 2, 3
• Starting dose: 10-20 mg daily (standard antidepressant dosing applies)

Sertraline

• Minimal breast milk excretion, infant receives <10% of maternal daily dose 1
• Produces very low or undetectable infant plasma concentrations 2, 3
• Preferred in recent ACOG guidelines for perinatal depression 4
• Starting dose: 25-50 mg daily

Alternative Agents (Use with More Caution)

Fluvoxamine

• Minimally excreted in breast milk 1
• However, 33% of reported infant-to-maternal plasma ratios exceed 0.10 1
• Less data available overall 2

Fluoxetine

• Avoid as first-line choice - highest infant plasma levels reported among SSRIs 3
• Suspected adverse effects documented in nursing infants 3

Citalopram/Escitalopram

• Higher infant plasma levels compared to paroxetine/sertraline 3
• Some concern for adverse effects, though limited data for escitalopram 2
• May consider if mother successfully used during pregnancy 3

Clinical Management Algorithm

Step 1: Drug Selection

• First-line: Paroxetine or sertraline
• If mother was stable on another SSRI during pregnancy, may continue same agent postpartum 3

Step 2: Infant Monitoring

• Observe for diminished suck, sleep disturbances, decreased growth 1
• Watch for irritability, jitteriness, feeding difficulties 1
• Monitor particularly during first 48 hours and first week 5

Step 3: Dosing Strategy

• Use lowest effective maternal dose 1
• Standard antidepressant starting doses apply (no special lactation dosing required)

Critical Counseling Points

Benefits vs. Risks Discussion:

• Untreated maternal depression carries significant risks to mother-infant dyad 1
• Absolute risk of clinically relevant negative infant outcomes is low with paroxetine/sertraline 6
• Breastfeeding should NOT be discontinued when antidepressant treatment is indicated 3

Common Pitfall to Avoid: Do not arbitrarily discontinue effective SSRI therapy due to breastfeeding concerns. The harm from untreated maternal depression typically outweighs the minimal infant exposure risk with preferred agents 1, 3.

Red Flags Requiring Immediate Evaluation:

• Infant excessive drowsiness or sedation
• Poor feeding or failure to thrive
• Respiratory distress
• Persistent irritability or abnormal tone

The evidence consistently supports that mothers requiring SSRI treatment should continue therapy while breastfeeding, with paroxetine demonstrating the most favorable pharmacokinetic profile, followed closely by sertraline 1, 2.